Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Cancer Vaccine Technologies: Current Progress and Future Perspectives
share announcement

Cancer Vaccine Technologies: Current Progress and Future Perspectives

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 15608

Special Issue Editor

Prof. Dr. Petr G. Lokhov

E-Mail Website
Guest Editor
Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, 119121 Moscow, Russia
Interests: metabolomics; personalized metabolomics; mass spectrometry; biomarker discovery; cancer vaccines; cancer proteomics; diagnostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of death worldwide, and the prevalence of cancer continues to increase because there is no effective and safe method of fighting cancer. Approaches approved by the FDA for cancer treatment have many serious side effects, and do not significantly increase overall survival. Vaccination may offer such therapy because it leads to long-term protection by activating the body’s natural defenses. Up to 100 cancer vaccines have already been clinically tested, but have not been successful. Therefore, it is necessary to review the current progress and future prospects for cancer vaccines. This Special Issue plans to give a comprehensive overview of the science and technologies in this field, including: research ideas, advances in strategies of cancer vaccine development, cancer vaccine R&D platforms based on neoantigens, antigenic essences, CAR-T, whole cancer cells and tumor-associated antigens, cancer vaccine manufacturing process development and quality control, delivery systems, and the most promising cancer vaccine candidates. Original research papers, communications, and review papers will be considered for publication.

Potential topics include, but are not limited to:

  • Overview of cancer vaccine R&D platforms;
  • Neoantigen vaccine platform;   
  • Antigenic essence platform;
  • Whole-cell cancer vaccines;
  • mRNA cancer vaccines;
  • CAR-T cell therapy;
  • TAA-based cancer vaccines;
  • Cancer vaccine candidates and targets;
  • Advances in manufacturing and quality control;
  • Pharmaceutical processes for cancer vaccines;
  • Advances in cancer vaccine adjuvants;
  • Advances in cancer vaccine delivery systems;
  • Combinatorial strategies with cancer vaccines.

Prof. Dr. Petr G. Lokhov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer vaccine
  • cancer vaccine platform
  • antigenic essence
  • neoantigens
  • whole-cell cancer vaccine
  • CAR-T cell therapy
  • mRNA cancer vaccine
  • manufacturing process development
  • delivery systems
  • quality control

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 950 KiB  
Review
The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
by Bryan J. Neth, Mason J. Webb, Ian F. Parney and Ugur T. Sener
Pharmaceutics 2023, 15(4), 1134; https://doi.org/10.3390/pharmaceutics15041134 - 03 Apr 2023
Cited by 6 | Viewed by 3159
Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the [...] Read more.
Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosuppressive microenvironment seen in GBMs, there has been a broad interest in immunotherapy. In both GBMs and other cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from the DCVax-L trial provide some promise for vaccine therapy in GBMs. There is also the potential that future combination therapies with vaccines and adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open to novel therapeutic strategies, such as vaccinations, and carefully await the results of ongoing and future trials. In this review of GBM management, the promise and challenges of immunotherapy with a focus on therapeutic vaccinations are discussed. Additionally, adjuvant therapies, logistical considerations, and future directions are discussed. Full article
(This article belongs to the Special Issue Cancer Vaccine Technologies: Current Progress and Future Perspectives)
►▼ Show Figures

Figure 1

17 pages, 4418 KiB  
Review
Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines
by Petr G. Lokhov, Elena E. Balashova, Oxana P. Trifonova, Dmitry L. Maslov and Alexander I. Archakov
Pharmaceutics 2023, 15(2), 661; https://doi.org/10.3390/pharmaceutics15020661 - 16 Feb 2023
Cited by 1 | Viewed by 1234
Abstract
In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. [...] Read more.
In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics. Full article
(This article belongs to the Special Issue Cancer Vaccine Technologies: Current Progress and Future Perspectives)
►▼ Show Figures

Figure 1

38 pages, 3632 KiB  
Review
mRNA-Based Therapeutics in Cancer Treatment
by Han Sun, Yu Zhang, Ge Wang, Wen Yang and Yingjie Xu
Pharmaceutics 2023, 15(2), 622; https://doi.org/10.3390/pharmaceutics15020622 - 13 Feb 2023
Cited by 12 | Viewed by 6613
Abstract
Over the past two decades, significant technological innovations have led to messenger RNA (mRNA) becoming a promising option for developing prophylactic and therapeutic vaccines, protein replacement therapies, and genome engineering. The success of the two COVID-19 mRNA vaccines has sparked new enthusiasm for [...] Read more.
Over the past two decades, significant technological innovations have led to messenger RNA (mRNA) becoming a promising option for developing prophylactic and therapeutic vaccines, protein replacement therapies, and genome engineering. The success of the two COVID-19 mRNA vaccines has sparked new enthusiasm for other medical applications, particularly in cancer treatment. In vitro-transcribed (IVT) mRNAs are structurally designed to resemble naturally occurring mature mRNA. Delivery of IVT mRNA via delivery platforms such as lipid nanoparticles allows host cells to produce many copies of encoded proteins, which can serve as antigens to stimulate immune responses or as additional beneficial proteins for supplements. mRNA-based cancer therapeutics include mRNA cancer vaccines, mRNA encoding cytokines, chimeric antigen receptors, tumor suppressors, and other combination therapies. To better understand the current development and research status of mRNA therapies for cancer treatment, this review focused on the molecular design, delivery systems, and clinical indications of mRNA therapies in cancer. Full article
(This article belongs to the Special Issue Cancer Vaccine Technologies: Current Progress and Future Perspectives)
►▼ Show Figures

Figure 1

23 pages, 1824 KiB  
Review
Salmonella as a Promising Curative Tool against Cancer
by Ram Prasad Aganja, Chandran Sivasankar, Amal Senevirathne and John Hwa Lee
Pharmaceutics 2022, 14(10), 2100; https://doi.org/10.3390/pharmaceutics14102100 - 01 Oct 2022
Cited by 11 | Viewed by 3506
Abstract
Bacteria-mediated cancer therapy has become a topic of interest under the broad umbrella of oncotherapy. Among many bacterial species, Salmonella remains at the forefront due to its ability to localize and proliferate inside tumor microenvironments and often suppress tumor growth. Salmonella Typhimurium is [...] Read more.
Bacteria-mediated cancer therapy has become a topic of interest under the broad umbrella of oncotherapy. Among many bacterial species, Salmonella remains at the forefront due to its ability to localize and proliferate inside tumor microenvironments and often suppress tumor growth. Salmonella Typhimurium is one of the most promising mediators, with engineering plasticity and cancer specificity. It can be used to deliver toxins that induce cell death in cancer cells specifically, and also as a cancer-specific instrument for immunotherapy by delivering tumor antigens and exposing the tumor environment to the host immune system. Salmonella can be used to deliver prodrug converting enzymes unambiguously against cancer. Though positive responses in Salmonella-mediated cancer treatments are still at a preliminary level, they have paved the way for developing combinatorial therapy with conventional chemotherapy, radiotherapy, and surgery, and can be used synergistically to combat multi-drug resistant and higher-stage cancers. With this background, Salmonella-mediated cancer therapy was approved for clinical trials by U.S. Food and Drug Administration, but the results were not satisfactory and more pre-clinical investigation is needed. This review summarizes the recent advancements in Salmonella-mediated oncotherapy in the fight against cancer. The present article emphasizes the demand for Salmonella mutants with high stringency toward cancer and with amenable elements of safety by virulence deletions. Full article
(This article belongs to the Special Issue Cancer Vaccine Technologies: Current Progress and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop